Mycophenolate mofetil in low-risk renal transplantation in patients receiving no cyclosporine: a single-centre experience | Zendy

Omer Raheem | Zendy; Pádraig Daly | Zendy; Patrick O’Kelly | Zendy; W.P. Shields | Zendy; Antonio J. Zimmerman | Zendy; Pradeep Mohan | Zendy; Richard Power | Zendy; D. M. Little | Zendy; Peter J. Conlon | Zendy; DA Hickey | Zendy

Open Access

Mycophenolate mofetil in low-risk renal transplantation in patients receiving no cyclosporine: a single-centre experience

Author(s) -

Omer Raheem,

Pádraig Daly,

Patrick O’Kelly,

W.P. Shields,

Antonio J. Zimmerman,

Pradeep Mohan,

Richard Power,

D. M. Little,

Peter J. Conlon,

DA Hickey

Publication year - 2011

Publication title -

nephrology dialysis transplantation

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 1.654

H-Index - 168

eISSN - 1460-2385

pISSN - 0931-0509

DOI - 10.1093/ndt/gfr263

Subject(s) - medicine , azathioprine , mycophenolate , mycophenolic acid , transplantation , regimen , incidence (geometry) , gastroenterology , surgery , population , immunosuppression , kidney transplantation , urology , disease , physics , environmental health , optics

We assess our long-term experience with regards the safety and efficacy of Mycophenolate Mofetil (MMF) in our low risk renal transplant population and compared it retrospectively to Azathioprine (AZA) immunosuppressive regimen. Patients and methods. Between January 1999 and December 2005, 240 renal transplants received MMF as part of their immunosuppressive protocol (MMF group). AZA group of 135 renal transplants was included for comparative analysis (AZA group). Patients received Cyclosporine was excluded from this study.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research